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Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by
impaired social interaction and communication, and restricted behavior and interests.
A disruption in the balance of excitatory and inhibitory neurotransmission has been
hypothesized to underlie these disorders. Here we demonstrate that genes of both
pathways are affected by ASD, and that gene expression of inhibitory and excitatory
genes is altered in the cerebral cortex of adult but not younger autistic individuals. We
have developed a measure for the difference in the level of excitation and inhibition based
on gene expression and observe that in this measure inhibition is decreased relative to
excitation in adult ASD compared to control. This difference was undetectable in young
autistic brains. Given that many psychiatric features of autism are already present at an
early age, this suggests that the observed imbalance in gene expression is an aging
phenomenon in ASD rather than its underlying cause.
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INTRODUCTION
Autism spectrum disorders (ASDs) are neurodevelopmental dis-
orders with impairments in social interaction, language or behav-
ior, and repetitive behavior or restricted interest. In the United
States 1 in 68 children has an ASD (Centers for Disease Control
and Prevention (US) and Centers for Disease Control and
Prevention (US) Epidemiology Program Office, 2014). ASDs are
highly heritable, yet currently only 20% of the cases have an
identified molecular cause (Rosti et al., 2014), suggesting a multi-
genic mode of inheritance for autism. This is consistent with the
popular hypothesis that ASDs result from an increased ratio of
excitatory/inhibitory (E-I) neurotransmission, with many vari-
ants and mutations of different genes leading to a disturbed
E-I balance (Rubenstein and Merzenich, 2003). In support of
this hypothesis, several lines of evidence point to alterations in
molecular components of inhibitory synapses leading to ASD
(Hussman, 2001; Baroncelli et al., 2011). For example, dupli-
cations on chromosome 15q11-q13, encompassing GABRB3,
GABRA5, andGABRG3 are associated with autism (Menold et al.,
2001) and reduced expression of several genes involved in central
inhibitory synapses of ASD individuals has been reported. Post-
mortem brain tissue showed a reduction of the inhibitory GABAA
and GABAB receptors in autistic individuals (Blatt et al., 2001;
Fatemi et al., 2009a,b, 2014; Oblak et al., 2009, 2010) as well as
a reduction of levels of GAD65 and GAD67, the enzymes that
are necessary to produce the inhibitory neurotransmitter GABA
(Fatemi et al., 2002).
Whilst several studies implicate decreased inhibition in autism,
alterations in excitatory synapses in ASD are less known. The
original genetic evidence for an excitatory role in the disturbed
E-I balance hypothesis was an association study identifying the
ionotropic glutamate receptor GRIK2, also known as GluR6
(Jamain et al., 2002; Rubenstein and Merzenich, 2003). This asso-
ciation was, however, not present in a later Indian population
study (Dutta et al., 2007). Furthermore, in addition to an exci-
tatory role, GRIK2 has been shown to depress inhibitory synaptic
transmission (Chergui et al., 2000). There has been little further
direct physiological evidence supporting the idea of disturbed
excitatory transmission in ASD. In blood, an increased level of the
excitatory neurotransmitter glutamate was identified (Shinohe
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et al., 2006), but the mechanisms underlying this observation are
far from clear. Using proton magnetic resonance imaging, both
increased and decreased levels of glutamate/glutamine have been
measured in different regions of the brains of ASD individuals
(Page et al., 2006; Bernardi et al., 2011; Horder et al., 2013), but
again it is unclear how this might affect the pathophysiology of
autism.
The popularity of the E-I imbalance hypothesis in the absence
of much direct evidence for a role of excitation prompted us to
attempt to quantify the relative strength of excitation and inhi-
bition in ASD patients and controls. First, we identified a list of
genes impacting excitatory or inhibitory neurotransmission and
checked this list for associations with ASD. We then used the
mean expression levels of the two sets of genes as proxy measures
for excitation (E) and inhibition (I) and their difference E-I. We
computed these measures for the samples from two publicly avail-
able ASD and control microarray datasets derived from cortical
brain tissue (Voineagu et al., 2011; Chow et al., 2012). Although
these datasets differ in age of individuals and precise cortical tis-
sue location, the findings from both studies agree, pointing to a
broader mechanism involved in the pathophysiology of autism.
MATERIALS AND METHODS
MARKER SELECTION
Marker genes for excitatory vs. inhibitory synapses were
selected by retrieving the human genes associated with specific
gene ontology (GO, version of September, 2013) terms from
amigo.geneontology.org (Table 1). We classified GO terms as
related to excitation based on proteins being present in excitatory
synapses or having a role in amplifying excitatory neurotrans-
mission or decreasing inhibitory neurotransmission. Conversely,
GO terms describing presence in inhibitory synapses, attenuation
of excitatory transmission or a tendency to increase inhibitory
neurotransmission were classified as related to inhibition. Thus,
the marker selection was based on protein function, blind to any
downstream analysis. Genes classed as having both excitatory and
inhibitory functions were removed from consideration.
ANALYSIS OF LITERATURE REPORTS OF LARGE SCALE MUTATION
STUDIES
Large-scale CNV and exome sequencing studies of autism were
identified (Pinto et al., 2010; Neale et al., 2012; O’Roak et al., 2012;
Sanders et al., 2012). Copy number variants and de novo protein
sequence variants were identified in supplementary information
from these studies and compared with blind-chosen excitatory
and inhibitory markers based on gene symbol. An additional
mutation study (Prasad et al., 2012), was found in the Simons
Foundation Autism Research Initiative (SFARI) GENE database
(Basu et al., 2009) located at www.sfari.org/resources/sfari-base.
MICROARRAY DATA PROCESSING
Voineagu dataset preprocessing
Raw microarray data from autistic and control cortical sam-
ples were downloaded from GEO, accession number GSE28521,
normalized and corrected using the lumiR and lumiExpresso
functions from the lumi package in R. Expression values for each
sample were extracted. Then correlations were computed between
all pairs of samples; several samples were excluded based on the
fact that they were poorly correlated with a replicate sample from
the same individual and also poorly correlated with other individ-
uals. Samples thus excluded were A_AN09730_T, A_AN17138_T,
A_AN09730_F, A_AN17777_T, C_AN00142_T, C_AN04479_T,
and A_AN17138_F. Remaining replicate samples were averaged
within an individual. This left 30 samples, 14 with autism and 16
controls. Mature samples of age 20+ years, composed of 9 cases
and 13 controls, were analyzed for excitatory and inhibitory gene
expression, as well as E-I difference, as described below. Eighty per
cent power to detect a significant result using a t-test is achieved
for mature samples at the α = 0.05 level at a standardized mean
difference (Cohen’s d) of 1.3 standard deviations.
Chow dataset preprocessing
Processed cortical data per array were downloaded from GEO,
accession number GSE28475, and averaged signals were plotted,
all vs. all. Inspection of correlation plots between samples revealed
a number of frozen DASL samples with poor correlation with
Table 1 | Blind marker selection based on Gene Ontology terms.
GO term (ID) Gene symbols
Excitatory synapse (GO:0060076) ACTR3; DLG4; ELFN1; FGFR2; GRIN1; LRRTM1; LRRTM2; NETO1;
NLGN3; NTRK2; SHANK1; SLC17A7; SRPX2; SYNDIG1; SYP; SYT1
Positive regulation of synaptic transmission, glutamatergic (GO:0051968) ADCYAP1; DRD1; EGFR; GLUL; NRXN1; NTRK1; NTRK2; PTGS2;
RELN; SHANK3; TNR1
Positive regulation of excitatory postsynaptic membrane potential (GO:2000463) DRD4; GRIN1; NRXN1; PRKCZ; RELN; SHANK1; SHANK3
Negative regulation of synaptic transmission, GABAergic (GO:0032229) ADRA1A; NPY5R; SLC6A1; STXBP1
Glutamate biosynthetic process (GO:0006537) GLUD1; GLUD2; GLS; PRODH; PRODH2
Inhibitory synapse (GO:0060077) CEP112; GABRG2; IQSEC3; MAF1; SLC32A1
Positive regulation of synaptic transmission, GABAergic (GO:0032230) GRIK1; PRKCE; TAC1; TACR1
Negative regulation of excitatory postsynaptic membrane potential (GO:0090394) CELF4; MTMR2; NPY2R; S1PR2
Negative regulation of synaptic transmission, glutamatergic (GO:0051967) ATAD1; DRD2; GRIK1; GRIK2; GRIK3; HTR2A; NPY2R; PLA2G6
Gamma-aminobutyric acid biosynthetic process (GO:0009449) GAD1
Regulation of synaptic transmission, GABAergic (GO:0032228) NF1
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most or all other samples: 15_1, 20_1, 31_1, 32_1, 45_1, 46_1,
49_1, 50_1, 51_1, 52_1, 57_1, 57_2, 61_1, 64_1, 69_1, 70_1, and
74_1. After exclusion of these samples, two samples, 22_1 and
23_1, showed good correlation with all remaining samples, so all
samples were quantile normalized to the combination of these
samples. Correlations were then computed between all pairs of
samples, revealing Pearson correlation coefficients greater than
0.9 for 41 brains, 22 control and 19 autistic. Mature samples of age
20+ years, composed of 6 cases and 7 controls, were assessed for
excitation, inhibition, and E-I difference. Eighty per cent power
to detect a significant result using a t-test is achieved for mature
samples at the α = 0.05 level at a standardized mean difference
(Cohen’s d) of 1.9 standard deviations. Secondarily, the same
analysis was performed on immature samples, younger than 15
years, composed of 11 cases and 11 controls. Eighty per cent
power to detect a significant result using a t-test is achieved for
immature samples at the α = 0.05 level at a standardized mean
difference (Cohen’s d) of 1.2 standard deviations.
Calculation of E and I
Probes for genes with excitatory and inhibitory effect were iden-
tified and those targeted to all splice forms or the only splice form
were retained. This left at least one probe per gene that could be
analyzed. If there were multiple cortical samples from one brain,
then they were averaged within a brain. Expression values for each
probe were then shifted and scaled to a range [0,1]. Scaled and
shifted expression values for genes for which there were multi-
ple probes were then averaged across probes. Finally, these scaled
and shifted expression values for excitatory and inhibitory type
genes were averaged to obtain E, I and E-I values for each brain.
Expression values for each probe in both datasets are provided in
Supplementary Data Sheet 1.
Chow dataset regression analysis with respect to age
Regression analysis of expression to deduce age effects was carried
out as follows. Non-linear least squares regression (nls function
in R) was used to fit a regression model; in that model a set
of ncase + ncontrol expression values were fitted to a regression
model described by Expression = A1 + B1∗age + A2∗weights +
B2∗weights∗age. The ncase + ncontrol weights were zero for con-
trols and 1.0 for cases. The principal outputs of the model
were the parameters A1, B1, A2, and B2 and their standard
errors.
We computed power to detect a correlation difference between
autism and control using the same models as used in our com-
putations. We assigned cases and controls simulated uniform
random ages between 0 and 50 years. Correlation was simulated
in 19 autistic samples and no correlation was simulated in 22 nor-
mal samples. Simulated correlations were in the range 0 ≤ R <
0.86 with 1000 replicates at each of 25 correlation levels. Eighty
per cent power to detect significant difference in correlation at
the α = 0.05 level was achieved at Pearson r = 0.81.
Chow dataset regression analysis with respect to nervous system
tissues
Regression analysis of expression was carried out using the same
method as described above, except that we analyzed group aver-
ages of markers of neuronal, astrocytic, oligodendrocytic, and
microglial cell populations. The normalized and then averaged
expression in each of the four tissues was compared to age in
cases and controls using the same non-linear model as described
above. Marker sets, microarray probe identifiers, and fitted model
parameters are found in Supplementary Table 1.
Mixed analysis of age and neuronal markers to explain excitatory
and inhibitory gene expression in the Chow dataset
The concern arose that observed age-related changes in excita-
tory and inhibitory gene expression in cases compared to controls
would be a reflection of changes in nervous system cell popula-
tions; this concern focussed particularly on neurons. To address
this, the neuronal cell population was represented by an aver-
age of neuron-specific markers (described above). Two terms
related to neurons were added to the age model, neuronal expres-
sion in controls and difference in neuronal expression between
cases and controls. To limit the number of parameters fitted
and minimize overfitting, the expression intercept (at age 0) in
cases was assumed to be the same as in controls and omitted.
As before, weights were assigned zero for controls and one for
cases. This resulted in a model with five parameters fitted to 41
data points: Expression = A1 + B1∗age + B2∗weights∗age +
C1∗neurons + C2∗weights∗neurons. Results of this analysis are
in Supplementary Table 1.
RESULTS
MARKER SELECTION
We selected two groups of genes, termed excitatory and inhibitory
as described in methods, based on a selection of gene ontology
(GO) terms. In principle, excitatory genes were considered to
amplify excitatory (glutamatergic) neurotransmission or attenu-
ate inhibitory (GABAergic) neurotransmission, whilst inhibitory
genes were considered to amplify inhibitory neurotransmission or
attenuate excitatory neurotransmission (Table 1). Genes classed
as having both excitatory and inhibitory functions were dropped
from our analysis. This led to a list of 38 excitatory genes and 21
inhibitory genes.
Components of the excitatory postsynaptic density derived
from human cortex (Bayes et al., 2011) were overrepresented in
our excitatory gene set (6.1 fold enrichment, p < 10−8, hyper-
geometric test) relative to the human genome background. Our
inhibitory gene set was not significantly enriched with postsynap-
tic density genes (1.6 fold enrichment, p = 0.13, hypergeometric
test).
MUTATIONS OF EXCITATORY AND INHIBITORY GENES IN ASD
INDIVIDUALS
We first asked to what extent known copy number variants
(CNVs) or damaging protein sequence variants were known for
our set of excitatory and inhibitory genes. A detailed examination
of literature reports of large scale studies of copy number varia-
tion and protein sequence variants (Pinto et al., 2010; Neale et al.,
2012; O’Roak et al., 2012; Sanders et al., 2012) revealed that some
of these genes are affected by mutation in autism. Examination of
the public database SFARI GENE (Basu et al., 2009) showed addi-
tional mutations identified in autistic individuals only (Prasad
et al., 2012). Eight mutations likely of damaging impact affected
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five excitatory genes and two putatively damaging mutations
impacted two inhibitory genes (Table 2).We usedmutations from
cases only to compute a measure of enrichment of mutations
in this gene set in autism using Poisson statistics; compared to
3281 total gene hits in autism, 10 putatively damaging hits in this
set of 59 genes do not reflect significant enrichment (1.2 fold;
p = 0.19, Poisson test). Focussing only on the likely-damaging
protein modifications from the studies of O’Roak et al. (2012),
Sanders et al. (2012), and Neale et al. (2012), we find 450 in the
genome in autism; compared to this, four hits in our gene set
reflect a nominally significant enrichment (3.6 fold; p = 0.006,
Poisson test). These preliminary findings are encouraging and
could motivate the investigation of this gene set in larger case-
control association studies, as has been done with other gene sets
(Kirov et al., 2012).
EXPRESSION OF EXCITATORY AND INHIBITORY GENES IS ALTERED IN
AUTISM
To gauge the impact of autism on excitatory and inhibitory trans-
mission, we considered two available studies which addressed
gene expression in autism in the human cortex (Voineagu et al.,
2011; Chow et al., 2012). We used cortical samples from both
studies; cortical samples in the Voineagu dataset, though het-
erogeneous, clustered strongly with other cortical samples irre-
spective of sample location (Supplementary Figure 1). Discarding
cerebellar samples and averaging cortical samples per individ-
ual in both datasets results in high correlation across all genes
between sample pairs (Supplementary Figures 2, 3).
Gene expression values from 38 excitatory genes and 21
inhibitory genes from each sample were normalized and aver-
aged amongst probes for the same gene and amongst samples
from the same individual (seeMaterials andMethods). Stratifying
samples by age of the donor and considering only samples
from donors of 20 years of age and older, we found con-
certed changes in the E-I measure in the data from both studies
(Figure 1). A reduction in inhibitory gene expression appears
to underpin the change in the balance of excitation and inhi-
bition in both studies. To a smaller extent, the Chow dataset
also showed reduction in excitatory expression in mature autistic
samples.
EXPRESSION DIFFERENCES IN MATURE AUTISTIC BRAIN ARE
AGE-RELATED
Given the observation that mature autistic brains show changes
in the balance of excitation and inhibition in mature samples,
we asked if this condition was life-long or age-related; some
expression changes in the aging autistic brain were reported by
Chow et al. (2012). We therefore performed the same analysis
on a younger set of Chow samples, aged less than 15 years, 11
with autism and 11 controls. In contrast to the mature sam-
ples, in which differences in excitation and inhibition were noted,
younger samples showed no difference in excitation and inhibi-
tion relative to normal samples (Figure 2, upper panel).
To better understand the effect of age on excitation and inhi-
bition in autism, we built combined linear models of expression
in the full set of 41 high-quality samples from Chow et al. (19
cases, 22 controls). This was done by fitting a unified least squares
model to the data. Control data were modeled as having a lin-
ear trend and autistic samples were modeled as having the same
trend, plus a difference in trend. This permitted us to assess the
significance of the difference between the age effects in cases and
controls (Figure 2, lower panel; Table 3). This analysis showed
Table 2 | Known mutations in ASD for excitatory and inhibitory genes.
Gene type Symbol Mutation (residue or Damaging? Condition Reference
genome coordinates, hg18)
Excitatory ELFN1 chr7:1754k-1774k Loss, exonic Autism SFARI, Prasad et al., 2012
Excitatory GRIK2 chr6:101961k-102006k Gain, intronic Autism SFARI, Prasad et al., 2012
Excitatory GRIK2 chr6:102425k-102437k Loss, intronic Autism SFARI, Prasad et al., 2012
Excitatory NRXN1 chr2:50722k-50730k Loss, exonic Autism SFARI, Prasad et al., 2012
Excitatory NRXN1 chr2:50708k-50721k Loss, exonic Autism SFARI, Prasad et al., 2012
Excitatory NRXN1 chr2:50421k-50908k Loss, exonic Autism SFARI, Prasad et al., 2012
Excitatory NRXN1 chr2:50722k-50730k Loss, intronic Autism SFARI, Prasad et al., 2012
Excitatory NRXN1 chr2:50913k-50958k Loss, intronic Autism SFARI, Prasad et al., 2012
Excitatory NRXN1 chr2:51045k-51127k Loss, exonic Autism SFARI, Prasad et al., 2012
Excitatory RELN p.Q417* Nonsense Autism Neale et al., 2012
Excitatory SLC6A1 p.A288V Missense Autism Sanders et al., 2012
Excitatory STXBP1 p.R551C Missense Autism Neale et al., 2012
Inhibitory CEP112 chr:1761133k-61139k Loss, intronic autism SFARI, Prasad et al., 2012
Inhibitory GAD1 - Silent Autism O’Roak et al., 2012
Inhibitory MTMR2 p.N283D Damaging Autism Sanders et al., 2012
Inhibitory NF1 p.H2459N Missense predicted
tolerated, benign
Autism Sanders et al., 2012
Inhibitory NF1 p.A2644V Missense, predicted
probably damaging
Control Sanders et al., 2012
Inhibitory NF1 chr17:26493k-26507k Loss, exonic Autism SFARI, Prasad et al., 2012
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FIGURE 1 | Summary of excitatory and inhibitory changes in cortical
samples from mature individuals. Expression for each probe scaled to the
range [0,1] and averaged across probes and individuals. Upper panel, six
autism and seven control samples in the Chow dataset: (A) Excitatory
expression, (B) Inhibitory expression, and (C) Excitatory-inhibitory difference.
Lower panel, nine autism and 13 control samples in the Voineagu dataset.
(D) Excitatory expression, (E) Inhibitory expression, and
(F) Excitatory-inhibitory difference. P-values were computed by Student t-test.
that both excitatory and inhibitory gene expression differ little
between autistic and control individuals at birth (E: p = 0.6; I:
p = 0.5). However, a decay in excitatory gene expression of 2.4%
per decade of life in cases compared to controls was observed
(model coefficient p = 0.04). A more severe relative decrease of
inhibition of 7.8% per decade was observed in inhibitory expres-
sion (model coefficient p = 0.02). Taken together, these decays
in excitation and inhibition resulted in a general increase in
net excitatory expression in autism that failed to significantly
diverge from the trend in aging controls (5.4% per decade of life,
p = 0.08).
DECLINE OF INHIBITION WITH AGE IS NOT EXPLAINED BY DECLINE IN
NERVOUS SYSTEM TISSUES
We tested whether our expression changes with age could be
attributed to generalized decreases in brain tissue with age. We
therefore isolated sets ofmarkers and relevant probes for neuronal
and glial tissues, following those identified by Kuhn et al. (2011).
Identical to our regression analysis of excitatory and inhibitory
markers, we analyzed the averaged expression of groups of cell-
type markers for neurons (NEFL, ENO2, SLC12A5, KCNQ2, and
SCN3A), astrocytes (GFAP, AQP4, and GJA1), oligodendrocytes
(MOG, MAG, MOBP, and MBP), and microglia (CD37 and
CD53). We found no age differences between cases and controls
in any of the groups of cell-type markers (Supplementary Figure 4
and Supplementary Table 1). Whilst in neurons there may be a
difference between cases and controls, our sample size is too low
to demonstrate this conclusively.
A more robust test for our excitatory and inhibitory expres-
sion patterns involves regressing out age as well as the neuronal
cell markers mentioned above in cases relative to controls. With
respect to neurons, our method is an implementation of so-called
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FIGURE 2 | Age-related changes in excitation and inhibition in autism.
Expression for each probe scaled to the range [0,1] and averaged across
probes and individuals. Upper panel, samples of age less than 15 years,
11 autism and 11 control. P-values computed by Student t-test.
(A) Excitatory expression, (B) Inhibitory expression, and
(C) Excitatory-inhibitory difference. Lower panel, fitted models of
excitatory and inhibitory molecule expression with age in years in autism
cases (red) and controls (black). Model parameters are given ± standard
error. (D) Excitatory expression does not change with age in controls
(fitted model equation: 0.40[±0.02] + 0.0[±7.4]∗10−4 ∗ age). However,
relative reduction in excitatory expression with age is significant in autistic
samples (fitted model equation: 0.014[±0.026] – 0.0024[±0.0011] ∗ age).
(E) Inhibitory expression does not change significantly with age in
controls (fitted model equation: 0.38[±0.04] + 0.0021[±0.0015] ∗ age).
However, relative reduction in inhibitory expression with age is significant
in autistic samples (fitted model equation: 0.039[±0.054] –
0.0057[±0.0023] ∗ age). (F) Difference between excitation and inhibition
does not decrease significantly with age in controls (fitted model
equation: 0.020[±0.031] – 0.0021[±0.0012] ∗ age). Relative to controls,
increase in E-I difference is also not significant (fitted model equation:
−0.026[±0.044] + 0.0033[±0.0019] ∗ age). Thus, decreases in excitation
and inhibition largely cancel in this small dataset.
Population Specific Expression Analysis (PSEA) (Kuhn et al.,
2011). Beyond PSEA, however, our analysis puts the expression
of neurons in competition with age to explain variation in gene
expression in cases and controls (see Materials and Methods).
If decreases in neurons are the sole explanation for the excita-
tory and inhibitory signals that we observe, this should leave
insignificant additional age effects (Table 3). In excitatory mark-
ers, we found a slight remaining extra negative trend with age in
cases, but this was not significant. A larger sample size would be
required to confirm this finding. However, in inhibitory markers,
there was a remaining extra negative trend with age in cases, and
this was nominally significant (Table 3). Subtracting E-I, there
is no significant difference between case and control samples,
as before. In other words, the general trends we report survive,
even after accounting for changes in broad expression of neuronal
markers.
DISCUSSION
We have conducted a study of excitatory and inhibitory
gene expression in autistic individuals, compared with nor-
mal individuals. Our classification of genes was obtained by
the blind choice of genes based on their annotated functions
in neurotransmission. Genes coding for proteins that tend to
amplify excitatory neurotransmission or attenuate inhibitory
neurotransmission were classified as excitatory. Conversely, those
that amplify inhibitory or attenuate excitatory neurotransmission
were classified as inhibitory. Genes annotated as participating in
both were excluded. Putatively damaging protein-altering muta-
tions in autism showed enrichment in this gene set.
Our study finds excitatory/inhibitory imbalance in ASD, but,
based on gene expression evidence, this imbalance only appears
and progresses with age. A literature survey revealed mutations
in ASD in both the excitatory and inhibitory gene sets. When we
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Table 3 | Fitted model values from regression analysis of neuronal
markers and age in the Chow dataset.
Data type Model parameter Parameter value ± SE p-value
Excitatory Intercept 0.21±0.03 < 10−8
Age in controls −0.000045±0.00049 0.9
Age, case-control
difference
−0.0011±0.0007 0.1
Neurons in controls 0.0018±0.0003 < 10−6
Neurons, case-control
difference
0.00012±0.00016 0.5
Inhibitory Intercept −0.055±0.048 0.3
Age in controls 0.0020±0.0008 0.018
Age, case-control
difference
−0.0027±0.0011 0.026
Neurons in controls 0.0042±0.0004 < 10−10
Neurons, case-control
difference
0.00034±0.00026 0.2
Excitatory- Intercept 0.27±0.06 < 10−4
Inhibitory Age in controls −0.0020±0.0010 0.049
Age, case-control
difference
0.0015±0.0014 0.3
Neurons in controls −0.0024±0.0006 < 10−3
Neurons, case-control
difference
−0.00023±0.00033 0.5
calculated a measure for the balance of excitation and inhibition,
based on gene expression of the two classes, we found, using a
t-test, that the balance is shifted toward less inhibition or more
excitation in the cerebral cortex of adult autistic individuals in
two independent datasets, whereas this difference is not found in
immature individuals in the Chow dataset. Unfortunately, there
were insufficient immature samples in the Voineagu dataset to
retest this finding there.
By further modeling inhibitory gene expression as a linear
functions of age in cases and controls in the Chow dataset, we
showed a significant trend toward reductions in inhibition with
age in cases relative to controls, in keeping with the t-test result.
Further modeling excitatory gene expression and E-I differences
as linear functions of age in cases and controls, these results at first
glance appear not to confirm the t-test results. However, to make
sense of these apparent discrepancies, it must be kept in mind
that a t-test for difference between cases and controls tests only
one parameter; the fitted linear model tests multiple parameters
simultaneously, resulting in less-robust parameter fits. In light
of this, it makes most sense to postulate, based on this dataset,
reductions in both excitatory and inhibitory gene expression with
age in cases compared to controls, but that the reductions of
inhibitory expression are more pronounced.
A concern arose that the changes in excitatory and inhibitory
gene expression we observe are merely a reflection of broader
changes in nervous system tissues, and especially neurons; how-
ever, introduction of neuronal marker expression to explain age-
related changes in inhibitory gene expression resulted in retention
of the nominally significant decrease in inhibition with age.
Much of the previous evidence supporting the imbalance
hypothesis consisted of separate studies reporting on a select
number of genes tested in a select number of brain regions.
While it was already clear that the expression of several genes
related to GABA-ergic signaling is reduced in autism (Blatt et al.,
2001; Fatemi et al., 2002, 2009a,b; Oblak et al., 2009, 2010),
it was yet not clear that this was a consistent finding for the
GABA-ergic pathway as a whole. Previous reports on reduced
inhibitory markers primarily used data from adult brains. The
Chow et al. (2012) dataset, whilst of low power, allowed us to
study the imbalance in a group of younger individuals. We found
no evidence of any imbalance early in life, whereas the increase
in E-I associated with autism appears to develop with age. As
autism can already be diagnosed before the age of 3 years, this
suggests that the E-I imbalance only develops in response to
other changes underlying ASD, rather than causing ASD. Greater
numbers of samples of a variety of ages will be necessary to
confirm this.
We observe two caveats regarding the results we report here.
The first caveat is that we quantify excitation-inhibition bal-
ance by a single summary value per individual, based on sam-
ples derived from a large brain region; this E-I value is based,
not on a functional measure of inhibition or excitation, but
on mRNA expression levels. Presumably both excitation and
inhibition are highly complex processes working differently at
different locations, on different timescales, and in different con-
texts. Obviously, the single value per individual is to a greater
or lesser extent insensitive to the complex architecture of exci-
tation and inhibition. Yet, confirmation that the E-I measure is
significantly reduced in mature individuals in two separate data
sets suggests that a fundamental component of the excitation-
inhibition balance can be captured this way.Whilst it is possible to
alter the physiological balance of excitation and inhibition using
drugs like diazepam, ASD has been resistant to drug treatment
and is thus not identical to an acute excitation and inhibition
imbalance.
Second, as mentioned above, our findings are based on a
small number of samples. This is a reflection of the paucity of
publicly available brain expression data from autism samples.
Larger sample sizes will be required to improve our knowl-
edge of how autistic brains are different than controls and how
the disorder evolves during life. Hypothesis-free approaches,
which involve sifting through raw expression data, as well as
hypothesis driven approaches like ours, are key elements of
an overall progress to understanding. Such studies as this one
can inform future study designs with respect to experimental
power.
In conclusion, our methods demonstrate usefulness for study
of the E-I balance in tissues derived from specific brain regions
or other disorders such as Rett syndrome, Angelman syndrome
and schizophrenia for which an E-I imbalance is hypothesized
(Dani et al., 2005; Fernandez and Garner, 2007; Gonzalez-Burgos
et al., 2011; Wallace et al., 2012). Insight into the mechanisms
that underlie neurodevelopmental disorders, especially those with
implications for broad mechanisms of neurotransmission as we
have analyzed here, might serve as a starting point for therapeutic
intervention.
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